Key result
Novel LDL-C and Lp(a) therapies target residual ASCVD risk affecting ~25% of the population.
Answers are grounded in this paper and cite their sources.
Dyslipidemia is an important risk factor for atherosclerotic cardiovascular disease (ASCVD). There are abundant and unequivocal data to indicate that low-density lipoproteins (LDL) are a cause of ASCVD. Reduction of plasma low-density lipoprotein cholesterol (LDL-C) by medical therapy such as statins, ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have proven to significantly reduce the risk of cardiovascular events. However, for many reasons, many patients are not able to achieve LDL-C levels recommended by guidelines on currently available therapies. This has led to the development of new drugs lowering LDL-C, such as inclisiran, bempedoic acid, and evinacumab, in the hope of reducing cardiovascular (CV) risk. Drugs targeting lipoprotein (a) (Lp[a]) also have a role in the prevention of atherosclerosis, with genetic studies having established that 20%-30% of the human population inherits plasma Lp(a) levels in the atherogenic range. In this paper, we will review the recent progress made in the approaches to LDL-C and Lp(a) therapeutic modulation.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2023) conducted a review in Dyslipidemia and atherosclerotic cardiovascular disease (ASCVD). Novel LDL-C (inclisiran, bempedoic acid, evinacumab) and Lp(a) lowering therapies was evaluated. Novel therapies targeting LDL-C (inclisiran, bempedoic acid, evinacumab) and Lp(a) aim to reduce ASCVD risk, noting 20%-30% of the population inherits atherogenic Lp(a) levels.
Synapse has enriched 10 related papers. Consider them for comparative context: